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Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in the United States. We 
explored the feasibility of active laboratory-based surveillance of CRE in a metropolitan area not 
previously considered to be endemic for CRE. We provide a framework to address CRE 
surveillance and to monitor changes in CRE incidence over time.
In the United States, 43 states have confirmed detection of Enterobacteriaceae that produce 
the Klebsiella pneumoniae carbapenemase (KPC).1 Other carbapenemases, including the 
New Delhi metallo-β-lactamase (NDM), have also been reported.2 As carbapenemase-
producing carbapenem-resistant Enterobacteriaceae (CRE) are not reportable in most 
jurisdictions, the true prevalence of these organisms in the United States is not known. 
Accurate surveillance data for CRE, particularly carbapenemase-producing CRE, are 
important and can provide situational awareness, improve understanding of CRE 
epidemiology, and contribute to CRE-specific infection prevention efforts.
The following describes efforts made by the Minnesota Department of Health (MDH), a 
participant in the Emerging Infections Program, funded and coordinated by the Centers for 
Disease Control and Prevention (CDC), to develop an ongoing active surveillance program 
of CRE in a metropolitan area not previously considered to be endemic for CRE.
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Fourteen laboratories, including three reference laboratories, were identified by hospitals, 
long-term acute care hospitals, long-term care facilities, and clinics in the two most 
populous counties in the Minneapolis-St. Paul metropolitan area (Hennepin and Ramsey 
County; population 1,661,065 in 2010). A telephone survey was conducted with the 
microbiology supervisor at each site with the purpose of understanding the method(s) used 
to detect carbapenem resistance and confirm carbapenemase production. We then used data 
gathered during the survey to design a 30-day pilot surveillance project.
Laboratories were asked to collect data on the number of unique Enterobacteriaceae isolates 
identified during a 30-day surveillance period. Isolates were from clinical cultures from all 
sites ordered independently by clinicians. No distinction was made with regard to infection 
or colonization.
Laboratories also submitted isolates that met the MDH CRE definition: nonsusceptible to 
imipenem (MIC ≥2 μg/ml), meropenem (MIC ≥2 μg/ml), or ertapenem (MIC ≥1 μg/ml).3 
Separate criteria were used for Morganella, Proteus, and Providencia spp. because of 
intrinsic mechanisms that increase the MIC of imipenem: resistant to imipenem (MIC ≥4 
μg/ml) plus nonsusceptible to meropenem or ertapenem. All laboratories used automated 
testing instruments (ATI) to determine the MIC of antibiotics according to the 
manufacturer’s specifications. Additional testing or interpretation (e.g. expert rules) beyond 
the results from the ATI was not considered in this project.
Total counts of Enterobacteriaceae and isolates meeting the CRE definition were submitted 
to the MDH Public Health Laboratory. Isolates were submitted with a submission form 
containing demographic data, culture site, facility where the specimen was collected, and 
susceptibility testing results. All submitted isolates underwent broth microdilution (BMD) 
susceptibility testing using GNX2F Sensititre plates (TREK Diagnostic Systems, Cleveland, 
OH) and polymerase chain reaction (PCR) testing for blaKPC and blaNDM.4
Institutional review board evaluation was not required due to the Minnesota State 
Communicable Disease Rule regarding reporting of CRE cases. In addition, the project was 
reviewed at CDC and was determined to be “non-research.”
Twelve of 14 laboratories (10 clinical, two reference) participated in the survey. Seven 
laboratories used the modified Hodge test to confirm carbapenemase production. No 
laboratories performed PCR for carbapenemase genes.
Twelve of 14 laboratories (11 clinical, one reference) participated in the 30-day pilot 
surveillance. Laboratories reported 7,534 unique Enterobacteriaceae during the 30-day 
period. Sixty (0.8%) isolates met our CRE definition for submission. Demographic data, 
location, and culture site of the submitted isolates are shown in Table 1. Of the 60 isolates, 
16 (27%) were also resistant to all third-generation cephalosporins (3GC).
Eight (13%) of 60 isolates were nonsusceptible to at least one carbapenem by BMD testing 
(3 E. cloacae, 1 E. coli, and 4 K. pneumoniae), and 52 were susceptible to all carbapenems. 
Five of the eight isolates (1 E. cloacae, 1 E. coli, and 3 K. pneumoniae), were also resistant 
to all 3GC tested (cefotaxime and ceftazidime). One hundred twenty individual 
Pereira et al. Page 2













susceptibility tests (i.e., 120 combinations of 60 isolates tested against ≥1 carbapenem) by 
ATI were compared with matched BMD test results. Major errors, defined as resistant by 
ATI and susceptible by BMD, are shown in Table 2; the proportion of major errors (i.e., 
carbapenem-resistant by ATI) was 74%.
PCR was performed on all isolates at the MDH Public Health Laboratory. Three of eight 
isolates nonsusceptible to a carbapenem by BMD testing were carriers of the blaKPC gene 
(all K. pneumoniae). These three isolates tested resistant to each of the carbapenems tested 
by ATI and all 3GC by both methods. All other isolates were negative for blaKPC and 
blaNDM genes.
We report on a pilot surveillance project conducted by MDH to determine the feasibility of 
ongoing active laboratory-based surveillance of CRE in the two most populous counties in 
Minnesota. Based on our CRE definition, we found a low incidence of CRE in our 
catchment area (0.8%). Among those submitted only three were blaKPC positive. Of the 60 
isolates that met our CRE definition by ATI, only eight met this definition by BMD testing.
The discordant results between ATI and BMD testing results raise questions about the 
reproducibility of carbapenem susceptibility results. Our data suggest that the incidence of 
major errors depend on the carbapenem or device used during susceptibility testing. Our 
pilot was not designed to measure the efficacy of susceptibility testing, and therefore we 
cannot make any determination with regard to these methodologies, however further 
investigation is warranted. Of note, carriers of blaKPC had high carbapenem MIC values and 
met our CRE definition regardless of the testing method.
We found that resistance to 3GC served as an additional selection criterion for identifying 
carbapenemase producers in lieu of other confirmatory tests. Adding 3GC resistance to our 
CRE definition would narrow the submitted isolates to 16, without eliminating the three 
blaKPC producers. Additional selection criteria, such as 3GC resistance, may add specificity 
for carbapenemase-producers and be beneficial in areas with low incidence of 
carbapenemase-producing CRE.
The time needed for laboratories to collect accurate Enterobacteriaceae counts was an issue 
that was identified during our surveillance pilot. Some laboratories had automated means of 
de-duplicating data. For laboratories without this option, the time required to collect total, 
de-duplicated counts was prohibitive to participation.
One limitation of the pilot was the lack of participation from two reference laboratories 
during the 30-day surveillance pilot. Limitations in time and resources may have contributed 
to this, as participation was largely voluntary. Whether their participation would have had a 
significant impact on the proportion of CRE identified is unknown; however, inclusion of 
reference laboratories should be a goal of future surveillance efforts. Another limitation of 
the pilot was PCR testing for only the blaKPC and blaNDM genes as these are the most 
common carbapenemases in the United States. Future surveillance could include testing for 
other known carbapenemases.
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These data provide new information regarding the presence of CRE in Minnesota, an area 
not considered to be endemic for CRE. The current pilot serves as a framework to address 
CRE surveillance and to monitor changes in the proportion and incidence of CRE over time. 
A more complete understanding of the limitations of detecting carbapenem resistance using 
ATI is needed as are phenotypic definitions that differentiate carbapenemase-producing 
CRE from non- carbapenemase-producing CRE. With this knowledge we can apply a 
functional CRE definition that allows for the tracking of carbapenemase-producing CRE.
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Table 1




Median age in years (range) 70 (0–93)









Surgical wound 2 (3%)
Note. LTACH, long-term acute care hospital; LTCF, long-term care facility.
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